ClinicalTrials.gg
CompletedNCT06498479Updated Oct 16, 2026

ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

A Phase 3 interventional study of HS-20093 and Topotecan in Small Cell Lung Cancer, sponsored by Hansoh BioMedical R&D Company. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
40th of 333
461 · median 63
Started
2024
with 51 others
Phase 3
57 of 365
23 open now
Registered
233rd of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 40th largest by enrollment of the 333 interventional ones that give a count, is one of 52 that started in 2024, is one of 57 in phase 3, and was the 233rd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).

Read the detailed description

This is a phase 3, randomized, open-label, multicenter study comparing HS-20093 with topotecan in patients with limited or extensive SCLC that had disease progression on or after first-line platinum-based regimen. Subjects will be randomized by a ratio of 1:1 to receive HS-20093 or topotecan until disease progression.

The primary objective of this study is to assess whether treatment with HS-20093 prolongs OS compared with treatment of topotecan among subjects with relapsed SCLC.

The secondary objectives of the study are to further evaluate the efficacy/safety of HS-20093. The exploratory objectives are to characterize the pharmacokinetics of HS-20093, evaluate E-R relationship, immunogenicity of HS-20093, B7-H3 protein expression and soluble B7-H3 expression.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects ≥18 years of age.
  2. or cytologically confirmed SCLC.
  3. Subjects who progressed on or after platinum-based regimens.
  4. Has at least 1 as defined per 1.1.
  5. (ECOG) performance status of 0-1.
  6. Minimum of more than 12 weeks.
  7. Females subjects must not be pregnant at screening or have evidence of non-.
  8. Men or women should be using adequate measures throughout the study.
  9. Subject has provided /assent prior to initiation of any study specific activities/procedures.

Exclusion criteria

Exclusion Criteria:

  1. Combined SCLC, any previous diagnosis of transformed SCLC or SCLC that has transformed to NSCLC.
  2. Chemotherapy-free interval ≤30 days.
  3. Has received prior treatment with anti-B7 homologue 3 (B7-H3) targeted agents.
  4. Has received prior treatment with topoisomerase I inhibitor, including ADC that consists of topoisomerase I inhibitor.
  5. Has inadequate before randomization as specified in the protocol.
  6. Untreated or symptomatic with exceptions defined in the protocol.
  7. Unresolved toxicity from prior anti-tumor therapy, defined as not having resolved to (CTCAE) version 5.0 grade 1 with exceptions defined in the protocol.
  8. History of other with exceptions defined in the protocol.
  9. Inadequate bone marrow reserve or organ dysfunction.
  10. Evidence of cardiovascular risks.
  11. Severe, uncontrolled or active cardiovascular diseases.
  12. Severe or uncontrolled diabetes.
  13. Severe or uncontrolled high blood pressure.
  14. bleeding or obvious bleeding tendency within 1 month before randomization.
  15. Severe arterial or venous thromboembolic events within 3 months prior to randomization.
  16. Severe infections within 4 weeks before randomization.
  17. Receiving systemic therapy within 30 days prior to randomization with exceptions defined in the protocol.
  18. The presence of active infectious diseases before randomization.
  19. Current hepatic encephalopathy, hepatorenal syndrome, or Grade B or more severe cirrhosis.
  20. History of interstitial lung disease, immunotherapy-induced pneumonitis, clinically moderate or severe pulmonary disease.
  21. History of severe neuropathy or mental disorders.
  22. Female subjects of ; female subjects who are breastfeeding or who plan to breastfeed while on study; female subjects planning to become pregnant while on study.
  23. Vaccination or of any level within 4 weeks before randomization.
  24. History of severe hypersensitivity reaction, severe infusion reaction or allergy to recombinant human or mouse derived proteins.
  25. Hypersensitivity to any ingredient of HS-20093, DNA topoisomerase I inhibitor or regimens of Topotecan.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    HS-20093

    Participants will receive HS-20093 as an intravenous (IV) infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle until a treatment discontinuation criterion is met as specified in the protocol.

    Drug: HS-20093

  • Active comparator
    Topotecan

    Participants will receive topotecan until a treatment discontinuation criterion is met as specified in the protocol.

    Drug: Topotecan

Interventions

  • HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.

  • Topotecan will be administered per drug label.

06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival is defined as the time interval from randomization to death due to any cause.

    Time frame: From the date of randomization to the date of death due to any cause; Up to approximately 4.5 years

Secondary outcomes

  1. Objective Response Rate (ORR) Assessed by Blinded Independent Central Review and Investigators

    Confirmed ORR is defined as the sum of the complete response (CR) rate and partial response (PR) rate as per BICR and investigator per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.

    Time frame: From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 4.5 years.

  2. Disease Control Rate (DCR) Assessed by Blinded Independent Central Review and Investigator

    Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD (or non-CR/non-PD) per BICR and investigator assessment per RECIST v1.1.

    Time frame: From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 4.5 years.

  3. Duration of Response Assessed by Blinded Independent Central Review and Investigator

    Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first documentation of progressive disease (PD) or death.

    Time frame: From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first; Up to approximately 4.5 years.

  4. Progression-free Survival Assessed by Blinded Independent Central Review and Investigator

    PFS is defined as the time interval from the randomization to disease progression as per BICR and investigator assessment or death due to any cause.

    Time frame: From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 4.5 years.

  5. Incidence and Grade of Participants With Treatment-emergent Adverse Events

    TEAEs are assessed based on NCI CTCAE v5.0.

    Time frame: From the date of first dose to the end of safety follow-up; Up to approximately 4.5 years.

07

Study locations

9 sites
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Jilin Cancer Hospital
    Changchun, Jilin, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • Shandong Cancer Hospital
    Jinan, Shandong, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality, China
  • The First Affiliate Hospital of GUANGZHOU Medical University
    Guangzhou, China
  • Tongji Hospital
    Wuhan, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Aug 2026, 25 months.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 25 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Sep 2026 → Aug 2026 and completion May 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2024
First posted
Jul 12, 2024
StartActual
Jul 4, 2024
Primary completionActual
Aug 20, 2026was Sep 2026
CompletionActual
Aug 20, 2026was May 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 China)
  • Beijing Cancer Hospital · Beijing, China
  • Shanghai Pulmonary Hospital · Shanghai, China
Show 2 removed
  • Beijing Cancer Hospital · Beijing, China
  • Shanghai Pulmonary Hospital · Shanghai, China
Oct 16, 2026
Primary completion
Sep 30, 2026→Aug 20, 2026 (actual)
Oct 16, 2026
Study completion
May 31, 2027→Aug 20, 2026 (actual)
Oct 16, 2026
Enrollment
460 (estimated)→461 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    2 sites added, 2 sites removed
    Show 2 added (2 China)
    • Beijing Cancer Hospital · Beijing, China
    • Shanghai Pulmonary Hospital · Shanghai, China
    Show 2 removed
    • Beijing Cancer Hospital · Beijing, China
    • Shanghai Pulmonary Hospital · Shanghai, China
    Primary completion Sep 30, 2026→Aug 20, 2026 (now actual)
    Study completion May 31, 2027→Aug 20, 2026 (now actual)
    Enrollment 460 (estimated)→461 (actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06498479
Responsible party
Sponsor
First posted
Jul 12, 2024
Start date
Jul 4, 2024
Primary completion
Aug 20, 2026
Completion
Aug 20, 2026
Last update
Oct 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risvutatug rezetecan

Start the discussion